过氧化物酶增殖体活化受体α/γ双重激动剂的研究进展

Advances in peroxisome proliferator-activated receptors α/γ dual agonists

过氧化物酶增殖体活化受体(PPAR)是治疗2型糖尿病等人类代谢疾病的新靶点。与单一的PPAR_γ激动剂相比,PPAR_α／γ双重激动剂可以产生协同作用,更具有开发潜力。现综述α-烷氧基苯基丙酸类、苯氧异丁酸类、苄基丙二酸衍生物类及其他类型的PPARα／γ双重激动剂的研究进展,并提出一些研究思路。

Peroxisome proliferator-activated receptor （PPAR） is a new target for the treatment of metabolic diseases including type 2 diabetes. Compared with single PPARγ agonists, PPARα/γ dual agonists with synergistic actions have the more potential for the development of new therapy. This paper reviewed advances in studies of α-alkyloxy phenylpropionic acids, phenoxyisobutyric acids, benzyl malonic esters and some other types of PPARα/γ dual agonists, which might provide ts for the further researches.